Work with LifeSpan to design a custom immunohistochemistry to address your specific biological question. Outsource the entire localization process without having to
worry about finding and characterizing target specific antibodies, sourcing and validating difficult-to-find tissues, and having the ability to interpret the resulting
immunostaining in relation to complex human pathologies.
TCR Screening Services
Test your therapeutic antibodies in immunohistochemistry against a broad panel of normal frozen human tissue types in order to determine potential unintended binding.
Our non-GLP TCR services are designed on the FDA recommendation outlined in their "Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use".
Human (tested or 100% immunogen sequence identity)
IHC - Paraffin (10 µg/ml), Western blot (1:500 - 1:3000)
Specificity and Use
HLA-DR antibody was raised against recombinant protein fragment containing a sequence corresponding to a region within amino acids 56 and 260 of Human HLA-DRB1.
Human HLA-DRB1. Predicted cross-reactivity based on amino acid sequence homology: mouse (82%), bovine (83%), cat (89%), dogs (86%), monkey (94%).
0.1 M Tris-glycine, pH 7, 20% Glycerol, 0.01% Thimerosal
Aliquot and store at -20°C. Minimize freezing and thawing.
For research use only.
HLA-DR is an MHC class II cell surface receptor encoded by the human leukocyte antigen complex on chromosome 6 region 6p21.31. The complex of HLA-DR and its ligand, a peptide of 9 amino acids in length or longer, constitutes a ligand for the T-cell receptor (TCR). HLA (human leukocyte antigens) were originally defined as cell surface antigens that mediate graft-versus-host disease, which resulted in the rejection of tissue transplants in HLA-mismatched donors.